CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...